Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Primary Biliary Cholangitis Therapeutics Market Size During 2025–2029?
The market size for primary biliary cholangitis therapeutics has seen rapid expansion in recent years. This market is expected to grow from $0.89 billion in 2024 to $1.01 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.3%. The historical period’s growth can be linked to several factors, including increasing awareness of autoimmune liver diseases, a rise in clinical evidence supporting advancements in liver function testing, greater investment in hepatology research, and the increasing prevalence of autoimmune diseases.
The primary biliary cholangitis therapeutics market size is projected for swift expansion in the coming years. It is predicted to attain $1.64 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.9%. This growth throughout the forecast period can be attributed to the increasing adoption of second-line therapies, a burgeoning pipeline of novel therapeutics, a rise in combination therapies, expanded global access to diagnostics and specialty care, and an increase in patient advocacy and education initiatives. Noteworthy trends in the forecast period encompass personalized treatment approaches, the broadening use of second-line therapies, a focus on non-invasive biomarkers, an emphasis on symptom management, and the integration of real-world evidence (RWE).
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp
Which Factors And Drivers Are Influencing The Primary Biliary Cholangitis Therapeutics Market In 2025?
The rising occurrence of liver conditions is anticipated to fuel the expansion of the primary biliary cholangitis therapeutics market in the future. These conditions encompass various ailments that hinder the liver’s proper operation, frequently resulting in inflammation, fibrosis, or hepatic insufficiency. The escalating incidence of liver disorders stems from increased alcohol consumption, since excessive intake of alcohol harms liver cells, causing inflammation and persistent liver ailments. Therapeutics for primary biliary cholangitis aid in managing liver diseases by addressing inflammation in the bile ducts, decelerating the advancement of the illness, and maintaining liver functionality. Such treatments enhance patient results through alleviating symptoms, improving life quality, and postponing the necessity for liver transplantation. As an example, the Centers for Disease Control and Prevention, a US-based government agency, reported that in March 2022, fatalities from chronic liver diseases in Texas climbed to 5,079, an increase from 4,930 recorded in 2021. Consequently, the growing frequency of liver diseases is stimulating the development of the primary biliary cholangitis therapeutics market.
Which Key Segments Fueling The Primary Biliary Cholangitis Therapeutics Market?
The primary biliary cholangitis therapeutics market covered in this report is segmented –
1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
4) By Use: Human, Veterinary
Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates
What Are The Latest Industry Trends Transforming The Primary Biliary Cholangitis Therapeutics Market?
Prominent companies within the primary biliary cholangitis therapeutics market are concentrating on creating advanced products and securing approvals, particularly for peroxisome proliferator-activated receptor agonists, to enhance bile acid metabolism and decelerate disease progression in patients. Peroxisome proliferator-activated receptor (PPAR) agonists refer to medications that activate PPAR proteins, which are responsible for regulating genes linked to metabolism, inflammation, and energy balance. As an example, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar). This approval is for the treatment of primary biliary cholangitis (PBC) in adults who have shown an insufficient response to ursodeoxycholic acid (UDCA) or cannot tolerate UDCA. This compound is an oral, selective PPARδ agonist that operates by activating the PPARδ receptor, thereby regulating genes involved in reducing liver inflammation, enhancing bile acid metabolism, and slowing the progression of primary biliary cholangitis (PBC).
Which Key Players Are Driving Competition In The Primary Biliary Cholangitis Therapeutics Market?
Major companies operating in the primary biliary cholangitis therapeutics market are F. Hoffmann-La Roche Ltd, Parvus Therapeutics, Novartis AG, Gilead Sciences Inc., Viatris Inc., Ipsen Pharma, Hanmi Pharmaceutical Co. Ltd., Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., Durect Corporation, COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics
Download The Full Report For Exclusive Market Findings:
Which Region Currently Holds The Largest Share Of The Primary Biliary Cholangitis Therapeutics Market?
North America was the largest region in the primary biliary cholangitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Primary Biliary Cholangitis Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25887&type=smp
Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Therapeutics Market 2025, By The Business Research Company
Primary Biliary Cholangitis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Liver Diseases Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Cholinergic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model